Nasdaq · Common stock
Odyssey Therapeutics (ODTX)
$19.30 −$0.30 (−1.53%)
- Day’s range
- $18.62–$19.68
- Volume
- 139,918
ODTX price history
ODTX closed at $19.30 on Oct. 26, 2026. Over the past year, its daily close ranged from $15.56 on July 8, 2026 to $28.76 on Sept. 4, 2026.
Data table: ODTX daily closes, the past year
| Date | Close |
|---|---|
| Oct. 26, 2026 | $19.30 |
| Oct. 23, 2026 | $19.60 |
| Oct. 22, 2026 | $19.08 |
| Oct. 21, 2026 | $19.00 |
| Oct. 20, 2026 | $18.99 |
| Oct. 19, 2026 | $18.10 |
| Oct. 16, 2026 | $17.17 |
| Oct. 15, 2026 | $17.57 |
| Oct. 14, 2026 | $16.60 |
| Oct. 13, 2026 | $17.24 |
| Oct. 12, 2026 | $18.26 |
| Oct. 9, 2026 | $19.00 |
| Oct. 8, 2026 | $18.12 |
| Oct. 7, 2026 | $18.08 |
| Oct. 6, 2026 | $18.13 |
| Oct. 5, 2026 | $20.84 |
| Oct. 2, 2026 | $20.73 |
| Oct. 1, 2026 | $20.42 |
| Sept. 30, 2026 | $22.22 |
| Sept. 29, 2026 | $22.44 |
| Sept. 28, 2026 | $21.47 |
| Sept. 25, 2026 | $20.51 |
| Sept. 24, 2026 | $19.93 |
| Sept. 23, 2026 | $20.76 |
| Sept. 22, 2026 | $23.34 |
| Sept. 21, 2026 | $23.06 |
| Sept. 18, 2026 | $24.38 |
| Sept. 17, 2026 | $23.22 |
| Sept. 16, 2026 | $23.12 |
| Sept. 15, 2026 | $21.99 |
| Sept. 14, 2026 | $24.26 |
| Sept. 11, 2026 | $24.63 |
| Sept. 10, 2026 | $23.64 |
| Sept. 9, 2026 | $24.51 |
| Sept. 8, 2026 | $26.97 |
| Sept. 4, 2026 | $28.76 |
| Sept. 3, 2026 | $26.40 |
| Sept. 2, 2026 | $26.62 |
| Sept. 1, 2026 | $24.50 |
| Aug. 31, 2026 | $24.52 |
| Aug. 28, 2026 | $24.36 |
| Aug. 27, 2026 | $25.98 |
| Aug. 26, 2026 | $25.62 |
| Aug. 25, 2026 | $26.23 |
| Aug. 24, 2026 | $25.15 |
| Aug. 21, 2026 | $26.39 |
| Aug. 20, 2026 | $24.67 |
| Aug. 19, 2026 | $24.25 |
| Aug. 18, 2026 | $21.95 |
| Aug. 17, 2026 | $20.86 |
| Aug. 14, 2026 | $20.73 |
| Aug. 13, 2026 | $20.72 |
| Aug. 12, 2026 | $21.58 |
| Aug. 11, 2026 | $20.35 |
| Aug. 10, 2026 | $22.17 |
| Aug. 7, 2026 | $21.17 |
| Aug. 6, 2026 | $21.55 |
| Aug. 5, 2026 | $20.89 |
| Aug. 4, 2026 | $19.96 |
| Aug. 3, 2026 | $18.13 |
| July 31, 2026 | $18.93 |
| July 30, 2026 | $18.42 |
| July 29, 2026 | $18.05 |
| July 28, 2026 | $18.43 |
| July 27, 2026 | $19.03 |
| July 24, 2026 | $18.66 |
| July 23, 2026 | $17.67 |
| July 22, 2026 | $18.61 |
| July 21, 2026 | $18.22 |
| July 20, 2026 | $17.58 |
| July 17, 2026 | $17.61 |
| July 16, 2026 | $17.06 |
| July 15, 2026 | $17.25 |
| July 14, 2026 | $17.31 |
| July 13, 2026 | $17.61 |
| July 10, 2026 | $16.69 |
| July 9, 2026 | $16.83 |
| July 8, 2026 | $15.56 |
| July 7, 2026 | $15.91 |
| July 6, 2026 | $16.47 |
| July 2, 2026 | $16.80 |
| July 1, 2026 | $16.61 |
| June 30, 2026 | $18.71 |
| June 29, 2026 | $18.89 |
| June 26, 2026 | $18.06 |
| June 25, 2026 | $17.80 |
| June 24, 2026 | $18.47 |
| June 23, 2026 | $18.55 |
| June 22, 2026 | $18.72 |
| June 18, 2026 | $19.07 |
| June 17, 2026 | $18.48 |
| June 16, 2026 | $17.87 |
| June 15, 2026 | $17.65 |
| June 12, 2026 | $16.90 |
| June 11, 2026 | $16.81 |
| June 10, 2026 | $16.20 |
| June 9, 2026 | $17.09 |
| June 8, 2026 | $17.12 |
| June 5, 2026 | $16.43 |
| June 4, 2026 | $17.00 |
| June 3, 2026 | $16.69 |
| June 2, 2026 | $16.93 |
| June 1, 2026 | $16.96 |
| May 29, 2026 | $17.01 |
| May 28, 2026 | $17.92 |
| May 27, 2026 | $17.19 |
| May 26, 2026 | $17.56 |
| May 22, 2026 | $17.50 |
| May 21, 2026 | $17.74 |
| May 20, 2026 | $16.97 |
| May 19, 2026 | $16.94 |
| May 18, 2026 | $17.39 |
| May 15, 2026 | $17.62 |
| May 14, 2026 | $17.32 |
| May 13, 2026 | $17.94 |
| May 12, 2026 | $17.90 |
| May 11, 2026 | $17.45 |
| May 8, 2026 | $16.42 |
Key figures
- Average daily volume
- 260,624Past 3 months
- Market value
- $927.5M
- Dividend yield
- —
Price change
- 1 month
- −5.90%
- 3 months
- +3.43%
What Wall Street says about ODTX
In the past 90 days, Wall Street firms published 4 rating or price-target actions on ODTX: 3 new ratings and 1 raised price target.
| Action | Rating | |||
|---|---|---|---|---|
| UBS | Initiates coverage | Buy | $27 | |
| Raymond James | Initiates coverage | Outperform | $42 | |
| HC Wainwright & Co. | Initiates coverage | Buy | $44 | |
| JP Morgan | Raises target | Overweight | $26 to $29 |
Ratings and price targets are the firms’ own opinions, reported as published.
Not investment advice.
About Odyssey Therapeutics, Inc. Common Stock
Odyssey Therapeutics Inc is a clinical-stage biopharmaceutical company seeking to transform the standard of care for patients suffering from autoimmune and inflammatory diseases. The Company is developing medicines that are designed to precisely target disease pathology with an initial emphasis on the innate immune system. Its programs include OD-07656, a small molecule scaffolding inhibitor of receptor-interacting protein kinase 2, or RIPK2, a small molecule scaffolding inhibitor of interleukin-1 receptor-associated kinase 4, or IRAK4, and OD-00910, an agonistic protein therapeutic targeting tumor necrosis factor receptor 2, or TNFR2, built from camelid heavy chain variable regions, or VHH, domains.
- Headquarters
- Boston, Mass.
- Listed
- May 8, 2026
- Sector
- Health care
- Industry
- Biological products, (no diagnostic substances)
In WallStreetDigest editions
No WallStreetDigest article about ODTX is on the site yet.